Author: Acosta, Anna M; Mathis, Adria L; Budnitz, Daniel S; Geller, Andrew I; Chai, Shua J; Alden, Nisha B; Meek, James; Anderson, Evan J; Ryan, Patricia; Kim, Sue; Como-Sabetti, Kathryn; Torres, Salina; Dufort, Elizabeth; Bennett, Nancy M; Billing, Laurie M; Sutton, Melissa; Keipp Talbot, H; George, Andrea; Pham, Huong; Hall, Aron J; Fry, Alicia; Garg, Shikha; Kim, Lindsay
Title: COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, March 1–June 30, 2020 Cord-id: 8amv62um Document date: 2020_11_9
ID: 8amv62um
Snippet: Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
Document: Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date